Noshin Noorjahan

[Cell Death & Disease] Mechanistic investigations revealed that KIF20A regulates DHX9 nucleocytoplasmic distribution and inhibits TRIM21-mediated K48-linked polyubiquitination at DHX9-K755, thereby preventing its proteasomal degradation and enhancing protein stability.

[Oncogene] Investigators revealed for the first time that 25-Hydroxyvitamin D (25(OH)D) exerts antitumor effects by promoting exon 13 skipping of KDM6A, which suppresses the proliferation and stemness of breast cancer cells and lacks H3K27 demethylase activity.

[FASEB Journal] Scientists elucidated the functional role of the potassium channel tetramerization domain 15 (KCTD15) in triple-negative breast cancer progression, providing mechanistic insights into its potential as a therapeutic target for this challenging disease.

[Discover Oncology] The authors synthesize current preclinical and clinical advancements in targeting CSCs via DNA damage response inhibitors, including PARP, ATR, ATM, and DNA-PKcs inhibitors, as well as emerging synthetic lethality targets.

[Novocure] Novocure announced that the US FDA approved Optune Pax^® for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.

[Cell] The authors deciphered that sensory neurons, the dominant neuron type in the triple negative breast cancer ecosystem, drive the immune-excluded tumor microenvironment by stimulating a dense extracellular matrix.